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The genomic diversity of 99 T4-like coliphages was investigated by sequencing an equimolar mixture
with Illumina technology and screening them against different databases for horizontal gene transfer
and undesired genes. A 9-phage cocktail was given to 15 healthy adults from Bangladesh at a dose of
3109 and 3107 plaque-forming units and placebo respectively. Phages were detected in 64% of the
stool samples when subjects were treated with higher titer phage, compared to 30% and 28% with
lower-titer phage and placebo, respectively. No Escherichia coli was present in initial stool samples, and
no ampliﬁcation of phage was observed. One percent of the administered oral phage was recovered
from the feces. No adverse events were observed by self-report, clinical examination, or from laboratory
tests for liver, kidney, and hematology function. No impact of oral phage was seen on the fecal
microbiota composition with respect to bacterial 16S rRNA from stool.
& 2012 Elsevier Inc. All rights reserved.Introduction
Eastern Europe has a long tradition of using bacteriophages
against bacterial infectious diseases for both prophylactic and
therapeutic application (Summers, 2001). Numerous phage cock-
tails are sold in Russian pharmacies as registered products. These
phage cocktails target two main disease complexes: diarrheal
diseases and pyogenic infections (Sulakvelidze et al., 2001). The
rise of antibiotic-resistant bacteria has rekindled the interest of
the Western medical community in the Eastern phage therapy
tradition (Merril et al., 2003). However, the scarcity of scientiﬁc
publications from Eastern Europe detailing the composition of
phage cocktails, their biological safety in human applications, and
their efﬁcacy in controlled clinical trials makes it difﬁcult toll rights reserved.
r),
@icddrb.org (S. Sultana),
rb.org (S. Huq),
dical Research, Division of
ueensland 4029, Australia.
esearch Centre, East Street,rationally evaluate phage therapy. Many Western scientists have
therefore remained skeptical towards the potential of this ther-
apy. Since alternatives to antibiotics are urgently needed for an
increasing number of bacterial infections, a systematic and critical
re-evaluation of phage therapy has become a public health
priority.
The safety issue of bacteriophage therapy for topical applica-
tion in humans has only recently been addressed in scientiﬁc
reports. A mixture of bacteriophages directed against Pseudomonas
aeruginosa, Staphylococcus aureus, and E. coli or a placebo was
applied on venous leg ulcers in 39 patients, and no adverse effects
were associated with the treatment (Rhoads et al., 2009). Likewise, a
group of 24 patients with chronic otitis externa (‘‘swimmer’s ear’’)
were topically treated with a P. aeruginosa phage preparation
(Wright et al., 2009) with no adverse effects. Furthermore, a
mixture of P. aeruginosa and S. aureus phages was developed for
topical application on the skin of burn patients (Merabishvili
et al., 2009), but the outcome of the ongoing safety trial has not
yet been reported.
In Eastern Europe, oral phage delivery is currently used against
intestinal infections (Sulakvelidze et al., 2001; Sulakvelidze and
Kutter, 2005). However, before the efﬁcacy of phage preparations
can be studied on large human cohorts, it is essential to ﬁrst
assess their safety in humans to ensure that they do not cause
adverse effects when applied orally. Previous animal toxicology
studies of laboratory mice receiving oral T4 phages have
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S.A. Sarker et al. / Virology 434 (2012) 222–232 223documented the presence of phage throughout the intestinal
tract, evidence of in vivo phage replication, and the noted absence
of adverse events (Chibani-Chennouﬁ et al., 2004a,b; Weiss et al.,
2009). Finally, the reference T4 phage T4D (T4D refers to the
individual classical T4 phage isolate NC_000866 herein to distin-
guish from T4 as a generic name for the whole phage group) was
tested in healthy adult volunteers from Switzerland without
adverse events (Bruttin and Bru¨ssow, 2005). Since it is reported
that temperate coliphages frequently carry virulence genes
(Canchaya et al., 2003), we chose to restrict our approach to the
best-characterized professional virulent (‘‘lytic’’) coliphage group,
namely T4-like Myoviridae, for which genomic analyses have not
revealed the presence of so-called virulence genes (Denou et al.,
2009; Bru¨ssow et al., 2004; Bru¨ssow, 2010).
Before a T4-like phage cocktail can be evaluated for its
therapeutic efﬁcacy in children hospitalized at ICDDR,B with
E. coli diarrhea, several safety and efﬁcacy issues posed by
clinicians had to be addressed. We present here further genetic
and clinical safety data on oral delivery of phages against E. coli
serotypes causing diarrhea. Phage cocktails are needed in order to
achieve a reasonable coverage of pathogenic E. coli strains for a
given clinical condition, and therefore the composition of the
cocktail might differ for different geographical regions or need to
be adjusted over time. Our ﬁrst objective was therefore to extend
the genetic safety analysis to our entire T4-like phage collection
of 99 T4-like phage isolates instead of sequencing the individual
phage genomes of those phages used in the current cocktail.
To address clinical safety and possible risks associated with
dosage, safety studies were repeated in the target population
from Bangladesh with a 100-fold higher dose of phage cocktail
consisting of different T4-like subgroups than the dosage used
in a previous safety study with Swiss healthy adult volunteers
(Bruttin and Bru¨ssow, 2005). This particular dosage and popula-
tion were used in this study before clinical trials could be
conducted with a 10-fold higher dose (than the Swiss study) in
older children, with the standard dose in young healthy children,
and to eventual administration of this dose to hospitalized
children.
A major drawback of antibiotics is their collateral damage to
bystander commensal microbiota, while phages are considered to
be target species-speciﬁc leaving the commensals unaffected. To
document this difference, we investigated the impact of oral
coliphage on the fecal microbiota in phage-treated adult
volunteers. 
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Fig. 1. Phylogenetic tree of g23 sequences of 98 phages in the NPC. All phages in the
NPC are represented here, with the exception of NPC 2022 due to poor g23 sequence
quality. The g23 of RB43 is included in the tree, although it was not sequenced with the
collection, and JS98 corresponds to NPC 1000. n indicates phages that were individual
components of the phage cocktail administered to volunteers within this study. Dotted
lines in the phenogram refer to negative branch lengths.Results
The T4 phage collection
The 99 T4-like phages that comprise our collection were
obtained from stool samples of pediatric diarrhea patients and
healthy children, sewage samples, and environmental water
samples from Bangladesh and Switzerland (Chibani-Chennouﬁ
et al., 2004a,b). The phages were isolated and ampliﬁed on an
E. coli strain K-12 derivative devoid of prophage lambda, and
T4-like classiﬁcation of phage was determined by a diagnostic
PCR (Te´tart et al., 2001) and/or electron microscopy (EM). The
diagnostic g23 PCR products were sequenced, and a tree was
constructed from the aligned sequences (Fig. 1). The tree analysis
allowed the distinction of three major groups in our phage
collection: 45 phage isolates clustered around the T4D reference
strain; 14 isolates were associated with RB69, the prototype of
another subgroup of T4 phages; and 36 phage isolates belonged to
still another subgroup of T4 phages represented by phage JS98.
Only one phage aligned with the RB49-like phage subgroup, whileno phages related to the reference phage RB43 were part of our
collection. Based on the g23 sequence, the T4D-like phage branch
showed a degree of sequence diversiﬁcation similar to that of
Fig. 2. Overlap of reads mapped to reference genomes of phage classes, in
millions. No reads were common among all four reference genomes or between
the RB69 and RB49 mappings.
Fig. 3. T4 sequence mapping showing areas of low coverage. Low coverage areas
are numerated and the corresponding genes found in that region are shown in
bold, followed by a short description. 1: gp60 topoisomerase II; gp60.1 hypothe-
tical protein; mobA DNA endonuclease; gp39 DNA topoisomerase II. 2: segF
homing endonuclease; gp56 dCTP pyrophosphatase. 3: usvX RecA-like recombi-
nation protein. 4: segA homing endonuclease; b-gt beta glucosyl transferase;
5: mobB DNA endonuclease. 6: nrdG anaerobic NTP reductase; mobC homing
endonuclease. 7: I-TevII homing endonuclease. 8: mobD homing endonuclease.
9: segB homing endonuclease; tRNA. 10: segC homing endonuclease; gp5.3
conserved hypothetical protein. 11: gp10 baseplate wedge subunit and tail pin.
12: gp11 baseplate wedge subunit and tail pin ; gp12 short tail ﬁbers; wac ﬁbritin
(whisker ﬁbers). 13: segD DNA endonuclease. 14: alt ADP-ribosyltransferase.
15: I-TevIII homing endonuclease (defective). 16: nrdB aerobic NDP reductase;
nrdB.1 hypothetical protein; mobE homing endonuclease. 17: I-TevI homing
endonuclease. 18: gp34 proximal long tail ﬁber. 19: gp36 hinge connector of long
tail ﬁber. 20: gp37 distal long tail ﬁber; gp38 adhesin.
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related to each other.
Sequencing of the T4 phage collection
Health authorities such as the FDA request the sequencing of
phage genomes in order to assess the genetic risk associated with
the application of phages. Foreseeing that phage cocktail compo-
sition may need to be adjusted in the future, we sequenced our
entire T4 phage collection instead of only sequencing the indivi-
dual phages components of the cocktail tested within this study.
The 99 phages of our collection were propagated individually,
their DNA was extracted, and equal amounts of phage DNA were
mixed for sequencing with the Illumina technique. Thirty-one
million 50 bp reads with a high sequencing quality above Q30
were obtained.
Sequence mapping was initially done with the ensemble of
reads in order to gain insight into the relatedness of NPC phages
to several reference genomes representing the main subgroups of
T4-like phages, namely T4, JS98, RB69, and RB49 (Supplementary
Table 1). The ratio of the reads aligned with the T4D compared to
the RB49 genome was 19:1 and thus very similar to the ratio of
T4D-like over RB49-like phages of 22:1 as determined by g23
sequencing. The same was true for the ratio of T4D over RB69
(2.7:1 and 3:1) and the ratio of T4D over JS98 (1.2:1 and 1.2:1)
obtained by aligned Illumina reads and g23 sequence-based
phage typing, respectively. This close association suggests ﬁrst,
that the DNA sequences were read proportional to the represen-
tation of the phages in the collection and second, that g23
sequences are a good predictor for attribution of the entire
genome sequences to distinct subgroups. Shared reads between
the subgroups were minimal: only a small proportion of
sequences could be attributed to two different subgroups (Fig. 2).
Sequence alignments with reference genomes
When projected on the T4D reference genome, an overall
coverage of 1460 reads per 50 bp region was obtained with our
Illumina sequence set. However, the coverage was not homo-
geneous: 20 regions were covered poorly (Fig. 3). Three long T4D
genome segments with low coverage were identiﬁed, including a
4-kb region encoding a baseplate wedge protein, tail pin, short
tail ﬁbers, and whisker ﬁbers. The high coverage over major parts
of the T4D reference genome demonstrates that many phages inour phage collection belonged to this group and shared close bp
identity with T4D.
According to the g23 sequence analysis, only two RB49 phages
were part of our collection. The observed average coverage of 80
for RB49 phages suggested that a single phage accounted for
40-fold coverage. Based on this approximation, regions of average
coverage suggest that at least 37 (1460 reads: 40 fold coverage)
T4D-related phages are in our collection which is close to the
number of 45 estimated from the g23 sequences (Fig. 4). The
regions of low coverage of the T4D genome indicated regions
which are speciﬁc to T4D or are found in only one further phage
from our cocktail. The sequence alignment with the T4D sequence
revealed 18,000 small nucleotide polymorphisms (SNPs). Loca-
lized clusters of sequence variation emerged from a homogeneous
background of bp diversity (Fig. 4). When analyzed for coding
sequences, there was a clear bias for bp changes to occur at the
third codon position, which did not lead to amino acid changes in
the encoded proteins (Fig. 5).
The average coverage of the JS98 genome with reads was 1150,
which, assuming homogeneous sequencing efﬁcacy, suggests that
at least 29 (1150 reads: 40 fold coverage) JS98-like phages were
in our collection and that is again close to the 36 JS98-like phages
in our collection diagnosed by g23 sequencing. However, the
coverage of the reference JS98 genome was, with the exception of
two small regions, even and fewer SNPs were observed than in
the T4D alignment (Fig. 4). These observations suggest less
diversiﬁcation in the JS98 subgroup than in the T4D subgroup,
which coincides with the analysis of the g23 tree structure (Fig. 1).
The RB69 genome showed only an average 550-fold coverage,
suggesting 14 (550 reads: 40 fold coverage) RB69-like phages
were in our collection, which comes very close to the 16 RB69-
like phages diagnosed by g23 sequencing. Only one RB69 genome
Fig. 4. Reference mapping to phage genomes (A) T4, (B) JS98, (C) RB69, and (D) RB49. Coverage of reference genome when mapped with the full set of Illumina reads and
conﬂict report of SNPs for those mappings. From outer to inner most ring: Coverage depth; coverage threshold; conﬂicts; scale.
Fig. 5. SNP distribution of reads mapped to the four subgroup reference genomes
T4, JS98, RB49, and RB69 by codon position, shown in %.
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region speciﬁc to the reference strain, and the RB69 SNP density
showed an intermediate level between T4D- and JS98-like phages
(Fig. 4). Only seven small regions of the RB43 phage genome werecovered with reads (data not shown) demonstrating that this
T4-like coliphage was not sampled in our survey.
Sequence analysis of the unmapped phage DNA
After removing repeated attributions, 10.5 million reads could
be aligned with the reference genomes of the four T4 phage
subgroups, accounting for 33% of total reads. It was considered
that the unattributed reads could have been from contaminating
bacterial DNA from the E. coli strain K-12 derivative on which the
T4-like phages from our collection were propagated. This was,
however, not the case, as only 0.02 million reads aligned with the
K-12 genome. Notably, these reads were not distributed evenly
throughout the E. coli genome, but were mapped to two small
regions of the bacterial genome (Supplementary Fig. 1). One
group of reads overlapped a tRNA-Lys gene, while the other
group mapped to yﬁD, a gene that encodes a pyruvate formate
lyase and catalyzes a step in anaerobic glycolysis. In the T4D
reference phage genome the corresponding gene is annotated as
vs.6 (Miller et al., 2003). It is located within a cluster of T4 genes
(vs.3 to vs.8), which otherwise lack database matches. Sequences
related to yﬁD were found in the sequenced genomes of several
T4- and RB69-like phages, but not in JS98-like phages. We tested
whether the possession of this gene provided a growth advantage
S.A. Sarker et al. / Virology 434 (2012) 222–232226under anaerobic conditions to the corresponding T4 phages by
comparing plaque counts under aerobic and anaerobic growth.
No relative titer increase under anaerobic culture was seen in
T4 phages possessing vs.6 (data not shown).
The plasmid pDM30 was added at a low concentration to the
T4-like phage DNA pool. This plasmid contained three antibiotic
resistance genes that served as positive controls for the screening
of undesired genes. The 4200 plasmid-speciﬁc reads achieved a
19-fold coverage of the entire plasmid genome, and such a small
amount of reads excluded plasmid DNA as a source for the
unattributed DNA reads.
In order to investigate the identity of unattributed reads,
redundant reads were removed from the total set of sequences
and reference mapping was repeated. The total number of 31
million reads was reduced to 3.7 million non-redundant reads, of
which 2.3 million reads could be mapped on the four T4 subgroup
reference phage genomes. Not accounting for shared reads, 24%,
15%, 17%, and 6% could be aligned with the reference phages T4D,
RB69, JS98 and RB49 of the four subgroups, respectively (Supple-
mentary Table 1). Reads that mapped to addition phage genomes
(JS-10 and JSE, data not shown), to E. coli K-12, or to the plasmid
were removed, and 1.37 million reads were left unattributed.
We projected these non-attributed reads on coliphage gen-
omes deposited in the NCBI database. Approximately 0.2 million
reads were attributed to T4-like phages wV7, RB51, and Shﬂ2.
These reads were not evenly distributed along the genome (which
would have suggested new subgroups), but clustered over distinct
genome regions (Supplementary Fig. 2). The conclusion that these
reads were not associated with new subgroups was further
conﬁrmed with g23 analysis, which placed these phages within
the T4D-like branch. An additional 0.1 million reads were aligned
with T4-like phages SP18 and vB-EcoM-VR7. They showed a
relatively even, but low coverage distribution on these genomes
(Supplementary Fig. 2). Their g23 sequence identiﬁed them as
distant members of the JS98 branch. Finally, 0.06 million reads
were aligned with T4-like phages IME08 and Bp7. Together, these
matches accounted for 0.29 million T4-related DNA reads.
Heterologous coliphage genomes from the NCBI database did
not contribute sequence matches with DNA from our collection,
except for Myovirus P1 and Siphovirus T1. The T4 phages from
our collection shared sequence relatedness with two genes
from P1. However, these were not phage genes, but rather mobile
genetic elements (insertion sequences IS1 and IS5). In contrast,
the T1 genome was covered with 0.03 million reads (Supplemen-
tary Fig. 3). The T1 genome was not covered over its entire length,
the coverage depth of the aligned regions was low, and showed
many SNPs.
We next explored the 1.37 million reads that could not be
attributed to the established four subgroups of T4-like phages by
yet another approach: 0.74 million could be de novo assembled
into 1523 contigs, with the longest being 21-kb long. Most contigs
were small (n¼862 were only 0.2–0.5 kb long), and only n¼234
contigs were larger than 0.5 kb. For 600 contigs the closest
homolog was shown to be a T4 phage from the four reference
subgroups (identity at the protein level). Almost exclusively, the
remaining contigs shared their best hits with T4-like phages from
enterobacteria. Most numerous were matches with E. coli phages
IME08, wV7, Bp7, VB_EcoM-vR7, RB32, and RB51, followed by
matches with T4-like Shigella phages SP18 and Shﬂ2 (data not
shown). The exceptions were matches with Siphovirus T1 DNA
encoding terminase, portal protein, major head, tail, tape mea-
sure, tail ﬁber genes and DNA primase, helicase, and Dam
methylase. Only one contig shared signiﬁcant sequence identity
with bacterial DNA (52% aa identity with the Enterobacter cloacae
enzyme deoxyheptonate aldolase, which is involved in aromatic
amino acid metabolism).Finally, BLASTN searches were used to investigate the 0.63
million non-redundant reads that could not be assembled into
contigs. When a random subset of 30,000 reads were analyzed by
BLASTN homology searches, 65% met stringency criteria to be
considered a positive hit. Of the positive hits, 95% of them gave a
hit with phages, practically all of which were represented by
T4-like phages.
Search for undesired genes
We screened all sequences from the phage collection sequen-
cing against three different databases; an internally maintained
database of undesired genes (DUG) and two public databases
compiling antibiotic resistance genes (ARDB) (Liu and Pop, 2009)
and bacterial virulence factor genes (VFDB) (Yang et al., 2008).
When the Illumina sequences were screened against the DUG, the
largest of the three databases, we obtained hits with 1555 entries
into the database. Practically all hits were represented by a single
50-bp match of phage sequence with the undesired genes. When
we asked for two or more 50-bp alignments from the phage
collection sequence pool with the database entries to qualify for a
hit, only 66 genes fulﬁlled this inclusion criterion, and these
matches were all investigated manually. Fifty-ﬁve of these hits
were with genes annotated as holin, lysin, tail ﬁber adhesion, tail
ﬁber assembly, integrases, and transposase genes, and thus
represented conventional phage genes. Of the 11 hits that
remained, these genes included several metabolite transporter
genes, a transcriptional regulator, and an elongation factor. The
search also identiﬁed an acridine resistance gene. However, this is
not an antibiotic resistance gene, but a T4 gene involved in phage
DNA replication (Rappaport et al., 1974; Wang and Ripley, 1998).
Weak and partial matches were observed with capsular poly-
saccharide synthesis, ferric citrate transport system of E. coli (Fec
system), and ferric enterobactin transport proteins (Fep genes).
No further hits were obtained when screened against the
ARDB and VFDB databases.
Clinical observation of adult volunteers for adverse effects
To assess the biological safety of our T4-like phages, a cocktail
of nine phage isolates from our collection was selected for
application in healthy adult volunteers from Bangladesh. The
phages were propagated individually on the non-pathogenic
E. coli strain K-12 and isolated by a combination of differential
centrifugation and sterile ﬁltration steps (Bruttin and Bru¨ssow,
2005). The phages were chosen based on their lytic activities on
pathogenic E. coli serotypes associated with pediatric diarrhea
(data not shown). Based on a previous safety test in Swiss adult
volunteers who were treated with 3107 pfu of total phage and
showed a good fecal bioavailability of the oral phage (Bruttin and
Bru¨ssow, 2005), we decided to use a 100-fold higher dose to test
for possible adverse effects before considering the extension the
safety tests to healthy and then hospitalized children.
The safety study group consisted of 15 healthy adult volun-
teers recruited by ICDDR,B. The volunteers received the phage at a
high dose (3109 pfu of total phage), at low dose (3107 pfu of
total phage), and placebo. Each subject received all three treat-
ments in a random order and thus served as his/her own control,
allowing for the detection of adverse effects with a small group of
exposed volunteers. However, this type of design, known as
repeated measures, uses internal controls and has no formal
control group, i.e. subjects were studied before the intervention
and also when given placebo to represent internal subject-speciﬁc
controls. This type of design presents some problems of analysis
since certain types of delayed effects cannot always be excluded.
Table 1
Characteristics of the study subjects and observation of abnormal observations in physical examination and clinical chemistry or hematology analyses according to
treatment mode for each individual volunteer.
Subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Normal range
Characteristics of subjects
Age (yr) 27 32 40 40 22 25 25 27 24 22 25 26 26 23 39
Sex m m m m m m f f f f f m m m m
Weight (kg) 63 59 60 57 57 67 49 51 53 54 54 65 68 59 59
Abnormal physical measures
Weight changes40.7 kg o0.7 kg (1.5%)
Pulse rate 60–100/min
Respiration rate 1,2 1 0,1 0 12–25/min
Fever 1,2 r37.5 1C
Systolic blood pressure 0,1,2 2 2 0 0,1 0 2 110–140 mmHg
Diastolic blood pressure 2 60–85 mmHg
Clinical chemistry
Naþ 1 136–145 mEq/L
Kþ 0 1 1 0 3.5–5.1 mEq/L
Cl 0 1 0 98–107 mEq/L
Total CO2 0,2 0,2 2 0 1,2 2 0,1,2 1 0,1,2 23–29 mEq/L
Ca2þ 2.1–2.6 mmol/L
Creatinine 1 80–115 mmol/La
Blood urea nitrogen 0 0 0 6–20 mg/dL
Total serum protein 0,1 2 0,1,2 0,1 0,2 0 0,1 0,2 0,2 6.0–8.3 g/dL
Albumin 3.4–5.4 g/dL
Total cholesterol 0,1 o5.18 mmol/L
Triglycerides 0,1,2 0,1,2 o1.7 mmol/L
Total bilirubin 0,1,2 5.1–17 mmol/L
Direct bilirubin 0,1 1.7–5.1 mmol/L
Alanine aminotransferase 1 0,1,2 2 o56 U/L
Aspartate aminotransferase 2 1 0,2 o40 U/Lb
gGlutamyl Aminotransferase o40 U/L
Fasting blood glucose 1 2 0 0,2 3.9–5.6 mmol/L
Hematology
Platelet count 0,1 170–500,000/mL
Red blood cell count 4.3–6.2106/mLc
Mean corpuscular volume 0 0,1 82–102 fLd
Mean corp. hemoglobin conc. 0 0 0 0 31–35 g/dL
Hemoglobin 2 13.2–16.2 g/dLe
Hematocrit 0,2 40–52%f
White blood cell count 0 0,1,2 1 0,2 0 3.9–11109/L
Neutrophils 0 1,2 2 45–74% WBC
Lymphocytes 0 1 2 2 0 25–45% WBC
Monocytes 0 2 0 1,2 3–7% WBC
Eosinophils 0,1,2 2 0,1,2 1 0,2 0,1,2 1–7% WBC
Adverse events 0g 1h 1i
The ﬁrst three rows give the physical characteristics (age in years, weight in kg, sex: m, male) of the 15 study subjects (columns).
The next six rows note individually for each subject if abnormal measurements were made during the physical examination. No indication means that the volunteers
showed only values that were within the normal range as deﬁned for the respective measurement in the last column. Abnormal measurements were noted with 0, 1 or 2 if
they were observed during the treatment with placebo (0), low phage (1) or high phage (2) preparation. If the abnormal values are italicized, an abnormal value for the
given value was already observed in the corresponding volunteer during the screening before any application of the test products. Many normal subjects who were judged
healthy for the local standard had ‘‘abnormal’’ values already at baseline, e.g. high eosinophil percentage, which might reﬂect local parasite and worm exposure.
The next rows give in a similar way observation of clinical chemistry values and hematology values which are outside of the normal range.
Notes: For a number of values the normal range is gender-speciﬁc. The last column gives the normal range for men. The respective values for women are as indicated here:
a, 53–97 mmol/L; b, o34 IU/L; c, 3.8–5.5106/mL; d, 78–101 fL; e, 12.0–15.2 g/dL; f, 37–46%.
Adverse events: g, abscess; h, mild dyspepsia; i, mild abdominal discomfort.
Reading examples: Volunteer 1 shows 0,1,2 for systolic blood pressure which means that he had blood pressure outside of the norm value when on placebo, low phage and
high phage. Volunteer 2 has no entry in systolic blood pressure meaning normal measurements during all treatment periods.
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and liver functions as well as the hematology status of the study
subjects, and questioned the subjects for gastrointestinal com-
plaints. The results of these analyses are summarized in Table 1.
Overall we did not observe a consistent pattern suggestive of
an adverse effect of phage therapy. Particularly, subjects showing
shifts in white blood cell proportions (volunteers 4, 6, 11, 15)
were not the same as those who showed elevated aminotransfer-
ase levels (volunteers 3, 5, 15); nor did they ﬁt to the subjects
who reported adverse events (volunteers 1, 8, 12). For details see
Supplementary text 1.Phage detection
Twenty-seven out of 42 investigated stool samples (64%) from
subjects treated with the high-titered oral phage dose yielded
phage on the E. coli indicator cell K-12. To be scored as phage-
positive, the stool sample had to contain 4100 pfu/g stool. In
comparison, 13 out of 44 stools (30%) from subjects treated with
the low-titered phage dose and 12 out of 43 stool samples (28%)
from subjects treated with placebo were phage positive. The same
prevalence of phage-positive stool samples was found using
the E. coli indicator strain WG-5. The data are heterogeneous,
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(p¼0.0006, Chi-square test). Moreover, pair wise comparisons
indicate statistical differences between high dose phage and the
other two groups (po0.001), but no difference was detected
between low dose phage and placebo (p40.05).
Two volunteers showed relatively high phage titers in the
feces when on placebo. This is not carry-over of high phage
application from the previous treatment since in one case the
high phage titer was detected in the ﬁrst week of treatment
(Supplementary Table 2, subject 15).
Only a single stool sample contained a higher phage titer than
that which was orally applied. In all other fecal samples, titers
were well below the level of orally applied phage. The median
titer of all phage-positive stools samples was 2102 pfu/g feces.
We estimated that less than 1% of the orally applied phage was
recovered from the stool (Supplementary Text 2).Fig. 6. DGGE proﬁles obtained with universal primers HDA1-GC and HDA2
targeting the V3 region of the 16S rRNA gene in bacteria from the stool of
15 adults from Bangladesh at baseline (B) and after (A) receiving all three
treatments over a 3-wk intervention period.
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Fig. 7. Bacterial community structure proﬁles for fecal samples from ﬁve human volunt
receiving placebo (subjects C1–C5). The proﬁles are given for day 1 (before ﬁrst interve
gives the fraction of 16S rRNA (in percent) ampliﬁed with universal primers targeting
sequences attributed to a speciﬁc phylum or family are depicted in different colors, thIn vitro experiments simulating stomach and duodenal gut
conditions suggested that the low pH value expected in the adult
stomach are detrimental to phage (Supplementary Table 3). With
this low survival of oral phage in Bangladeshi adults, and the low
amount of protein that even the high phage dose represents (less
than a microgram), it was not surprising that neither phage, nor
LPS (as contamination of the phage preparation), nor phage-
speciﬁc or LPS-speciﬁc antibodies were detected in the serum of
the study subjects.
DGGE
A frequently quoted advantage of oral phage over antibiotic
application is the lack of impact of phage on the gut microbiota
beyond the target species (Sulakvelidze et al., 2001). This is
particularly the case for E. coli phages, where the target patho-
genic bacterium in healthy subjects represents only a small
minority of the gut bacteria. The enrolled volunteers did not
show E. coli colonies in their stool samples (o102 pfu/g feces on
EMB or McConkey agar). Lack of effect of oral phage on the gut
microbiota has, however, not been demonstrated in humans. To
investigate this effect, we used two different experimental
approaches to assess changes in the gut microbiota composition.
In the ﬁrst approach, bacterial DNA was extracted from the fecal
samples of the volunteers at admission and at the end of the 3-wk
safety study. PCR was performed targeting the V3 region of the
16S rRNA gene using universal primers. The PCR products were
then analyzed by denaturing gradient gel electrophoresis (DGGE)
for band pattern variation for each individual volunteer before
and after application of all three test products (Fig. 6). Proﬁles
were unique for each individual, as expected. Pair wise calcula-
tions using the Dice’s similarity scores showed that proﬁles from
the same subject were on the average Dsc¼85.4% similar. The
difference between the two stool samples from the same subject
collected before and after the intervention was rather small for
some volunteers (Dice’s similarity scores Dsc¼92.1, volunteer 2),
while it was more substantial for other individuals (Dsc¼78.0,
volunteer 11).8d 1d 3d 8d 1d 3d 8d 1d 3d 8d 1d 3d 8d
oC1 PlaceboC2 PlaceboC3 PlaceboC4 PlaceboC5
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eers receiving the high dose T4 phage cocktail (subjects A1–A5) and ﬁve volunteers
ntion) and for days 3 and 8 (i.e. 1 and 6 days after the intervention). The top panel
the V4 region at the phylum level and the bottom panel at the family level. The
e color code is given at the right side.
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Next, we investigated stool samples from ﬁve volunteers
treated with placebo and ﬁve volunteers treated with the high
dose of oral phage. Stool samples were taken from the volunteers
just before phage administration, and then one and ﬁve days after
the 2-d application of the test products to the volunteers. We only
used stool samples collected during the ﬁrst week of intervention
to avoid interference by previous treatments. When DNA was
extracted and sequenced, approximately 1200 sequence reads
were obtained per stool sample and were assigned to bacterial
taxonomic categories. Sequencing data from the V1þV2
and the V4 region gave comparable results for the same stool
samples. Hence, only results from the V4 region are presented in
detail.
At the phylum level, the majority of 16S rRNA sequences were
assigned to Firmicutes, Actinobacteria, and Bacteroidetes
(in decreasing order) with small contributions coming from
Proteobacteria and Spirochetes (Fig. 7, Top). Firmicutes were
present in all 30 investigated stool samples and represented,
with one exception (subject C4, day 1), the numerically dominant
bacterial phylum. At family rank, Firmicutes were mainly repre-
sented by Streptococcaceae, Lachnospiraceae, Ruminococcaceae,
and Erysipelotrichaceae (Fig. 7, Bottom). Subjects with high fecal
read numbers for Streptococcaceae showed at the operational
taxonomic unit (OTU) level annotations of Streptococcus lutetiensis
(10% of all reads). Actinobacteria and Bacteroidetes were the next
most frequent fecal annotations. Bacteroidetes were at the genus
level mostly Prevotella. Actinobacteria were represented mainly
with Biﬁdobacteriaceae and Coriobacteriacieae. At the OTU
level the dominant Biﬁdobacterium species was Biﬁdobacterium
ruminantium (5% of all reads).
Many subjects showed changes in the relative abundance of
Actinobacteria and Bacteroidetes over the 8-d observation period.
However, there were no consistent trends and no differences were
seen between placebo and phage recipients. Enterobacteriaceae were
detected in all but one subject, but they represented, with one
exception, only 0.5–2.0% of the reads. Phage application was not
associated with an abundance decrease of Enterobacteriaceae.
The ratio of bacteria before and after the intervention was
analyzed for the major fecal bacterial families (data not shown).
Data points from phage recipients overlapped those from placebo
recipients. When the fecal microbiota data were compared for
overall bacterial diversity and richness at strain level (99%
identity), phage-treated subjects displayed the same range as
placebo-treated patients (Supplementary Fig. 4).Discussion
Our ﬁeld survey of coliphages in Bangladesh and Switzerland
led to a phage collection containing 99 T4-like isolates belonging
to four previously described subgroups (T4D-, RB69-, JS98- and
RB49-like phages). Our survey covers only a short time period and
only two, although very diverse geographical regions (Chibani-
Chennouﬁ et al., 2004a,b), and thus might not explore the full
diversity of T4-like coliphages. As we used a g23-based PCR test as
inclusion criterion for phages into our collection, we might have
selected against more distantly related T4-like coliphages which
gave only weak g23 PCR signals. A further limitation might be the
use of a single E. coli indicator strain.
When considering the genome structure of lambdoid coli-
phages (Casjens and Thuman-Commike, 2011), one might wonder
whether the g23 sequence is a reliable marker for the genome
diversity of T4-like phages. By projecting the sequences from our
collection on the genomes of established T4 subgroups, we couldget an independent estimation for the contribution of established
subgroups to our collection. This approximation came very close
to the attribution of the phages based on their g23 sequences,
therefore conﬁrming g23 as a reliable marker for the entire
genome classiﬁcation. This result might appear trivial, but it
underlines that the modular mode of evolution displayed by
lambdoid phages does not apply to T4-like phages. In the latter,
the vast majority of the genome is conserved within a subgroup
(‘‘conserved core’’) (Comeau et al., 2007, 2010), which diversiﬁes
mostly by the accumulation of point mutations, the shufﬂing of
single genes via mini-circles (Arbiol et al., 2010), and only in some
genome segments by modular exchanges (Te´tart et al., 1998).
From the genetic safety point of view, this characteristic of T4-like
phages is a clear advantage over the pervasive modular mode of
evolution in lambdoid phages. The knowledge of the g23
sequence alone thus predicts a vast majority of the genome
sequence.
This monotonous mode of evolution does not exclude hori-
zontal gene transfers (HGT) between E. coli and T4 phages
and between different T4 phages (Arbiol et al., 2010). In fact,
T4 phages shared a tRNA gene and a gene encoding a glycolytic
enzyme. The latter gene is probably a HGT from E. coli to some
(T4, RB69), but not other (JS98) T4-like phages. The 98% bp
identity between yﬁD of E. coli and v.6 of T4 suggests a recent
HGT event. Whether this gene provides a selective beneﬁt to
T4 phages possessing v.6 could not be determined, as increased
growth under anaerobic conditions was not associated with this
gene. A phage possessing a glycolytic enzyme does not represent
a genetic risk, and T4D containing the v.6 gene was tested in Swiss
volunteers without producing adverse effects (Bruttin and
Bru¨ssow, 2005).
When considering the non-redundant DNA reads, 2.3 out of
the 3.7 million reads (62%) were mapped on the four established
T4 subgroups, and subsequently raised the question about the
source for the remaining 38% of reads. Part of them projected on
T4-like phages like vB_EcoM-VR7 (Kaliniene et al., 2011), which is
according to the g23 tree analysis a peripheral member of the JS98
subgroup. Another part projected on T4-like phages like RB51, an
inner member of the T4D g23 branch, which showed unique DNA
sequences over particular genome regions. Half of the remaining
1.4 million reads could be assembled into 1523 contigs, the
majority of which matched T4-like phage genomes. In addition,
the obtained DNA sequences were also screened against the
genomes of non-T4 coliphages deposited in the database. We
found sequences that matched two genes of phage P2, but
otherwise genes from other taxonomical groups of coliphages
were conspicuously absent, suggesting that T4 phages are rela-
tively resistant against HGT from other coliphage classes. We
detected sequences that covered more than half of the T1
reference genome through sequence mapping, and in parallel
analysis of de novo contig assembly. T1 genes within assembled
contigs were found in the vicinity of other T1 genes, frequently in
the same order as in the T1 genome map, and never in the vicinity
of T4 phage genes. This display pattern of T1 genes therefore did
not provide evidence of gene exchange between T1 and
T4 phages, but most likely of a T1 phage contaminating one of
our T4 phage isolates. T1 was never introduced into our labora-
tory, but a phage was once isolated from stool which resembled
T1 in morphology (Chibani-Chennouﬁ et al., 2004a,b). T1 is
difﬁcult to remove from laboratories working with E. coli due to
its high resistance to desiccation (Rotman et al., 2010). However,
T1 does not represent a genetic risk since it does not carry
undesired genes (Roberts et al., 2004). In addition, with primers
based on the obtained T1-like sequences, it would be possible to
screen the individual phage isolates for the T1 contaminant and
eliminate the identiﬁed phage isolates from our collection.
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cannot be achieved by genome analysis, but ultimately from
in vivo tests in animals and in humans. In the present study we
gave a cocktail of nine T4-like phages from our collection
representing three of the four subgroups to adult volunteers,
and we did not observe adverse effects. We used a large number
of clinical and laboratory tests to detect harmful effects on liver,
kidney, gut, and hematology functions. The phage dose was 100-
fold higher than in a previous safety test with Swiss volunteers.
One may still contend that the absolute amount of phage given to
the volunteers was still low, corresponding to only a few micro-
grams of phage protein, and indeed, this dose was lower than that
determined to be necessary to achieve treatment effects in
previous animal studies (Jamalludeen et al., 2009). However,
phage doses as high as 1011–1012 pfu would present problems
with product availability and costs.
Corresponding in vitro experiments suggested that stomach
acidity was a major block to a higher phage transit and may
account for the fact that less than of 1% of orally applied phage
was recovered in the feces. This current study ﬁgures into a series
of planned clinical trials aimed ultimately towards pediatric
hospitalized diarrhea patients, for which a much lower dose than
that of the current study would be used. Since only the high and
not the low dose of phage led to fecal phage detection and was
signiﬁcantly higher than in placebo recipients, such a phage dose
might seem problematic. This problem can be remediated by
applying the phage together with bicarbonate, which leads to a
transient neutralization of stomach acidity and much better fecal
phage recovery (Jamalludeen et al., 2009). This approach is also
common practice for human application of phages in Russia and
Georgia (Sulakvelidze and Kutter, 2005). However, since stomach
acidity is also a major hurdle against enteric over-infection in
patients hospitalized on a diarrhea ward, we aimed to avoid
bicarbonate application. Children have a lesser acidic stomach
content than adults and phage transit might be correspondingly
better when administered to children, even without the use of
bicarbonate. Therefore a lower dose may prove to be sufﬁcient.
The fact that we achieved gut transit with the high phage dose,
even in the absence of bicarbonate, led us to believe that one can
achieve therapeutically efﬁcient doses in E. coli diarrhea patients.
In theory, phage is a self-amplifying antimicrobial agent (Payne
and Jansen, 2003) and even the low doses used in the present test
should reach therapeutic levels after replicating on the target
pathogen in the gut. If the same amount of phage is given orally to
patients suffering from acute E. coli diarrhea, we cannot, however,
automatically anticipate safety of the treatment. Phage may
amplify to high titers in the intestine and cause side effects not
observed under the conditions of the present test, such as a
massive release of lipopolysaccharide (‘‘endotoxin’’) from phage-
lysed E. coli cells. Therefore, further safety trials will have to be
conducted with T4-like phages in subjects acutely infected with
E. coli diarrhea.
The current volunteers did not contain E. coli in the feces, and
thus the lack of phage ampliﬁcation was not surprising. Consider-
ing that phages are target species-speciﬁc, the lack of a signiﬁcant
impact of oral phage application on the fecal microbiota composi-
tion was expected. In DGGE analysis, the Dice band-based
coefﬁcient values ranged from 78% to 92%. Similar values were
reported for stool samples from four Belgian subjects collected
over three months (Vanhoutte et al., 2004). This conservation of
the fecal microbiota strongly contrasts with the deleterious
impact of antibiotics on the gut commensals that fulﬁll not only
physiological, but also protective functions.
Finally, the small number of volunteers and the use of a repeated
measure approach on the same volunteers presented certain limita-
tions to our safety evaluation. However, based on the presented datawe obtained the approval of the ethical committee to pursue the
safety evaluation ﬁrst in healthy children and, if uneventful, also in
diseased children. In addition, one should not forget that unintended
large scale safety test with orally applied phages are conducted daily
in millions of consumers of fermented food like yoghurt, cheese, and
sauerkraut, which contain inevitably bacteriophages directed against
the starter bacteria used in food production. No adverse effects linked
to dairy phage exposure were ever reported. Furthermore, T4-like
phages are, as also demonstrated by our ecological survey, natural
members of the human gut ecosystem and we only isolated and
ampliﬁed what was already naturally present in the gut.Subjects and methods
Recruitment of volunteers
Thirty healthy adult volunteers were screened in a periurban
community of Nandipara, located 12 km from the International
Center for Diarrheal Diseases Research (ICDDR,B) in Dhaka,
Bangladesh. Subjects were recruited if they had not suffered from
diarrhea or other illness in the preceding two weeks, if their blood
count, liver and kidney functional tests were normal, and if they
were negative for antibodies to hepatitis A, B, C and E virus.
Further exclusion criteria were systemic infection, body-mass
index (BMI) below 21, use of prescription drugs during the last
two weeks, antibiotic use during the last four weeks, drug or
alcohol abuse, a clinically signiﬁcant medical history, or abnormal
vital signs. The purpose of the study was explained to the
volunteers in the local language and those willing to comply with
the study procedure and who signed a written informed consent
were enrolled.
Safety study
The study was a single-centered, randomized, double-blind,
placebo-controlled trial consisting of a three period cross-over
comparison for two different doses of an oral T4-like phage
cocktail. The dose of 3107 pfu was chosen because a previous
trial with Swiss adults showed that this dose resulted in phage-
positive stools in all volunteers with peak stool titers of
3104 pfu/g. This dosage was estimated sufﬁcient to control
bacterial targets within the gut. The higher dose of 3109 pfu
was chosen to test for dose-dependent adverse effects. The
phages were puriﬁed as described previously (Bruttin and
Bru¨ssow, 2005): the stock was diluted into 150 mL mineral water
and given as three divided doses of 50 mL during daytime, 6 h
apart. This treatment was given over two days followed by a
wash-out period of ﬁve days. The placebo consisted of the
corresponding volume of mineral water (Vittel, Nestle´) without
added phage. Vittel water has a pH of 7.3 and contains 258 mg
bicarbonate per liter as a weak buffer against gastric acidity. The
time line for the product application and medical examination of
the subjects is given in Supplementary Fig. 5. The product
attribution to the subjects was made according to a randomiza-
tion table elaborated by a biostatistician.
Adverse events were deﬁned as signs, symptoms or laboratory
analyses in the volunteer that could not be related to their current
health status whether or not they have a causal relationship with
the application of the study product. During the days of observa-
tion, the volunteers were on the usual diet of the ICDDR,B
hospital; the loss of wage was compensated, but no ﬁnancial
remuneration was paid to discourage participation for economic
needs. The clinical protocol (ICDDR,B research protocol #2008-
062) was ﬁrst evaluated by external scientiﬁc reviewers and
subsequently approved by two independent Institutional Review
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Ethical Review Committee (ERC) (RRC approval on May 11, 2006
and ERC approval on July 26, 2006). The study started March 7,
2007 and ﬁnished on April 30, 2007.
All clinical and laboratory observations were compiled in an
electronic ﬁle, which was sent to the Nestle´ Research Centre
(NRC). When all data had been compiled, the code was broken to
prepare the report requested by the ERC.
Phage cocktail
The cocktail consisted of nine independent isolates of T4-like
E. coli phages, including four phages closely related to the T4D
reference phage: phages NPC (Nestle´ Phage Collection) 1008,
NPC 1009, NPC 1031 and NPC 1003; four JS98-like coliphages:
NPC 1000, NPC 1024, NPC 1002 and NPC 1007 and one RB49-like
coliphage: NPC 1006. All phages were tested for T4-like phage
morphology and purity by negative staining electron microscopy;
g23 gene sequencing (Te´tart et al., 2001) conﬁrmed that the
chosen phages belonged to deﬁned T4-like phage subgroups
(Zuber et al., 2007) with at least two completely sequenced phage
representatives showing no undesired genes with respect to
human or environmental safety (Bru¨ssow, 2010).
Phage tests
Phage titration in stool samples was done with plaque assays
on the two E. coli indicator strains K-12 and WG-5, as described
previously (Bruttin and Bru¨ssow, 2005). Total daily stool volumes
were not measured. To convert the measured phage density in the
stool (expressed as pfu/g stool) into a stool phage output, we used
data on stool output of healthy adults from a comparable
population. Compared to Western communities, the population
from developing countries showed higher stool weight, higher
frequency of defecation and shorter transit times linked probably
to their diet which is higher in ﬁber and lower in fat. In this
control population the mean 24 h stool weight was 4087133 g
and 2957102 g in men and women, respectively. Daily stool
weight increased by 42 g for every 10 kg increase in body weight
and 27 g for every 10 years increase in age (/www.ams.ac.ir/aim/
index.htmlS).
Phage T4-neutralizing antibodies were determined by the
plaque reduction test as described previously (Denou et al., 2009).
Stability test
The phage cocktail or individual T4-like phages were incu-
bated in the following solutions (0.05 M Tris–HCl pH 7 and 8;
0.05 M glycine–HCl pH 3; 0.5 M KCl–HCl pH 2) at 371C for the
time indicated in the text. As speciﬁed, trypsin (Type XI from
bovine pancreas, T-1005 Sigma, St. Louis), pepsin (P-7000, Sigma)
pancreatin (from porcine pancreas, P-1750, Sigma) or porcine bile
extract (B-8631, Sigma) were added singly or in combination. The
outcome measure was the survival of phage infectivity as deter-
mined in plaque assays.
LPS
Lipopolysaccharide (LPS, endotoxin) was detected in the serum
samples with the Limulus amoebocyte lysate test (Charles River,
Wilmington, Mass.). E. coli LPS-speciﬁc antibodies were deter-
mined by ELISA with isotype-speciﬁc anti-IgA-, anti-IgM- and
anti-IgG-antibody conjugates as described previously (Bru¨ssow
et al., 1990).Denaturing gradient gel electrophoresis (DGGE)
Fecal bacteria proﬁles of predominant groups were assessed by
DGGE at baseline and after three weeks. Bacterial DNA extraction,
PCR ampliﬁcation of the 16S rRNA gene and DGGE analysis was
done as described previously (Jaquet et al., 2009; Tannock et al.,
2004).
Microbiota proﬁling by pyrosequencing
DNA was extracted from fecal samples using the GNOME kit
(BIO 101, La Jolla, CA, USA) as previously described (Firmesse
et al., 2008). The primers for PCR were designed as recently
described (Frank et al., 2008; Hamady et al., 2008). The details for
PCR, pyrosequencing and the analysis of the sequence data for
microbiota analysis were done as described previously (Claus
et al., 2011).
Sample preparation, sequencing, and sequence mapping
Phages were ampliﬁed and their DNA extracted as described
previously (Chibani-Chennouﬁ et al., 2004a,b). A sample pool was
created of equimolar concentrations of phage DNA from the
99 phages in the NPC and the pDM30 plasmid. Samples were
processed in vitro to generate a DNA template library of short
inserts following a genomic shotgun protocol (Fasteris SA, Swit-
zerland). High-throughput DNA sequencing was performed using
Hi-Seq 2000 technology (Illumina) to produce 50 bp reads.
Sequencing quality of the reads was veriﬁed using FASTQC
(version 0.10).
All reads were mapped to phage reference genomes (NC_000866,
EF469154, NC_004928, NC_005066, NC_007023, EU863409, and
EU863408), to the bacterial genome of the host strain used for phage
ampliﬁcation (NC_000913), and to the pDM30 plasmid, which con-
tained resistance genes to chloramphenicol, ampicillin, and tetra-
cyclin. Additional sequence mapping were done of the following
phage reference genomes: wV7 (HM997020), RB51 (NC_012635),
Shﬂ2 (NC_015457), IME08 (NC_014260), Bp7 (HQ829472), SP18
(NC_014595), vB_EcoM_VR7 (NC_014792), Shﬂ1 (NC_015456), T1
(NC_005833), P1 (NC_005856), T5 (NC_005859), TLS (NC_009540),
lambda (NC_001416), Stx1 (NC_004913), HK97 (NC_002167), Mu
(NC_000929), P4 (NC_001609), phiEco32 (NC_010324), P22
(NC_002371), T7 (NC_001604), N15 (NC_001901), T3 (NC_003298),
EPS7 (NC_010583), and WV8 (NC_012749). The mappings were
performed using Seqman NGen software (version 3, DNAstar) and
were further analyzed for coverage, redundancy, and conﬂicts.
In order to reduce the complexity, reads with a 100% sequence
identity were removed from the total reads to generate a set of
non-redundant (nr) reads, and this set of reads was used again for
sequence mapping against various reference genomes. Nr reads
were then mapped against all genes present in an in-house
Database for Undesirable Genes (DUG), described previously
(Denou et al., 2009) in a safety screening, in addition to being
screened against two public databases compiling antibiotic resis-
tance genes (ARDB) and bacterial virulence factor genes (VFDB).
Only hits having two or more reads aligned and covering more
than 30% of the gene were considered as positive hits and were
further investigated.
A de novo assembly was performed with the non-redundant,
non-mapping reads using default parameters of SeqMan NGen.
The contigs obtained were manually inspected for their closest
homolog from blastx matches in the nr protein NCBI database.
Reads not assembled into contigs were analyzed for their closest
homolog from blastn matches within the EMBL database
(e-valuer1.00E-4, coverageZ80%, percent identityZ95).
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The g23 of NPC phages were ampliﬁed using MziaI (50 TG-
TTATsGGTATGGTwCGyCGTGCTAT 30) and CAP8 (50 TGAAGT-
TACCTTCACCACGACCGG 30) primers as follows: 30 cycles of 30 s
denaturation at 96 1C, a 2 min annealing at 62 1C, and 3 min
extension at 72 1C. PCR products were sequenced by Fasteris, SA.
Sequences were trimmed to an averaged quality score threshold
of 12 and then aligned by the Clustal W method (Thompson et al.,
1994) in MegAlign (DNAstar).Funding
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